CureVac - Ingmar Hoerr, CEO
Added on 29 Mar 2017
Watched
3,315
times
CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.
КОММЕНТАРИИ
Ваш аккаунт без аватарки
Чтобы приступить к размещению комментариев, выберите временную аватарку:
Confirm
Что-то пошло не так. Попробуйте еще раз.
Or
Загрузить на 'Аккаунт Y8'
Отменить